Clearside Biomedical gains on Q4 profit

Clearside Biomedical,

11/03/2022 11:54

** Shares of drug developer  CLSD  rise 32.6% to $1.79
before the bell - on track to hit highest levels in over a
month, if gains hold  
    ** Stock among top pct gainers premarket across U.S.
exchanges
    ** CLSD posts Q4 profit of 31 cents/shr vs a loss of 14
cents/shr in year-ago period  urn:newsml:reuters.com:*:nGNX9ypqhW
    ** Cash equivalents of $30.4 mln at Dec. 31, 2021 and $10
mln milestone payments received in Q1 sufficient to fund
operations into Q2 2023 - Co 
    ** Plans to add a fourth cohort to its early-stage trial of
eye disorder drug, CLS-AX, for exploring broader range of doses 
    ** Up to Thursday's close, CLSD down ~51% YTD 

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))